Bibliografías temáticas / Juvenile idiopathic arthritis, adalimumab, immunogenicity

Índice

  1. Artículos de revistas
  2. Tesis
  3. Actas de conferencias
  4. Informes

Literatura académica sobre el tema "Juvenile idiopathic arthritis, adalimumab, immunogenicity"

Autor: Grafiati
Publicado: 10 de marzo de 2023

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Juvenile idiopathic arthritis, adalimumab, immunogenicity".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Artículos de revistas sobre el tema "Juvenile idiopathic arthritis, adalimumab, immunogenicity"

1

Doeleman, Martijn J. H., Erik M. van Maarseveen y Joost F. Swart. "Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis". Rheumatology 58, n.º 10 (26 de febrero de 2019): 1839–49. http://dx.doi.org/10.1093/rheumatology/kez030.

Texto completo
Resumen
Abstract Objective The clinical impact of anti-drug antibodies (ADAbs) in paediatric patients with JIA remains unknown. This systematic review and meta-analysis aimed to summarize the prevalence of ADAbs in JIA studies; investigate the effect of ADAbs on treatment efficacy and adverse events; and explore the effect of immunosuppressive therapy on antibody formation. Methods PubMed, Embase and the Cochrane Library were systematically searched to identify relevant clinical trials and observational studies that reported prevalence of ADAbs. Studies were systematically reviewed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses and appropriate proportional and pairwise meta-analyses were performed. Results A total of 5183 references were screened; 28 articles, involving 26 studies and 2354 JIA patients, met eligibility criteria. Prevalence of ADAbs ranged from 0% to 82% across nine biologic agents. Overall pooled prevalence of ADAbs was 16.9% (95% CI, 9.5, 25.9). Qualitative analysis of included studies indicated that antibodies to infliximab, adalimumab, anakinra and tocilizumab were associated with treatment failure and/or hypersensitivity reactions. Concomitant MTX uniformly reduced the risk of antibody formation during adalimumab treatment (risk ratio 0.33; 95% CI 0.21, 0.52). Conclusion The association of ADAbs with treatment failure and hypersensitivity reactions indicates their clinical relevance in paediatric patients with JIA. Based on our findings, we recommend a preliminary course of action regarding immunogenicity of biologic agents in patients with JIA. Further strategies to predict, prevent, detect and manage immunogenicity could optimize treatment outcomes and personalize treatment with biologic therapies.
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Marzan, Katherine Anne B. y Andreas Otto Reiff. "Adalimumab in juvenile rheumatoid arthritis/juvenile idiopathic arthritis". Expert Review of Clinical Immunology 4, n.º 5 (septiembre de 2008): 549–58. http://dx.doi.org/10.1586/1744666x.4.5.549.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Magli, Adriano, Raimondo Forte, Pasqualina Navarro, Giustina Russo, Francesca Orlando, Loredana Latanza y Maria Alessio. "Adalimumab for juvenile idiopathic arthritis-associated uveitis". Graefe's Archive for Clinical and Experimental Ophthalmology 251, n.º 6 (1 de marzo de 2013): 1601–6. http://dx.doi.org/10.1007/s00417-013-2275-x.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Denisova, R. V., E. I. Alexeeva, K. B. Isaeva, T. V. Sleptsova, T. M. Bzarova, S. I. Valieva, E. V. Mitenko et al. "ADALIMUMAB IN TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS". Current pediatrics 12, n.º 6 (7 de diciembre de 2013): 123. http://dx.doi.org/10.15690/vsp.v12i6.887.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Simpson, K., N. Marlow, J. Shaw y А. V. Rudakova. "PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS". Pediatric pharmacology 9, n.º 4 (12 de agosto de 2012): 48. http://dx.doi.org/10.15690/pf.v9i4.390.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Ramanan, Athimalaipet V., Andrew D. Dick, Ashley P. Jones, Andrew McKay, Paula R. Williamson, Sandrine Compeyrot-Lacassagne, Ben Hardwick et al. "Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis". New England Journal of Medicine 376, n.º 17 (27 de abril de 2017): 1637–46. http://dx.doi.org/10.1056/nejmoa1614160.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Tynjala, P., K. Kotaniemi, P. Lindahl, K. Latva, K. Aalto, V. Honkanen y P. Lahdenne. "Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis". Rheumatology 47, n.º 3 (28 de noviembre de 2007): 339–44. http://dx.doi.org/10.1093/rheumatology/kem356.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Aksenov, A. V. y E. A. Ivanovskaya. "Successful Use of Adalimumab in Children with Uveitis-Associated Juvenile Idiopathic Arthritis". Doctor.Ru 20, n.º 10 (2021): 73–75. http://dx.doi.org/10.31550/1727-2378-2021-20-10-73-75.

Texto completo
Resumen
Objective of the Paper: To describe clinical cases of successful use of adalimumab in children with uveitis-associated juvenile idiopathic arthritis (JIA). Key Points. One of the extraarticular manifestations of JIA is uveitis, i. e. inflammation of the vascular tract of the eye. JIA-associated uveitis is diagnosed primarily in small girls with oligoarthritis, early seronegative polyarthritis; in patients with arthritis associated with enthesitis and psoriatic arthritis. The article describes clinical cases of the use of adalimumab in JIA and uveitis where the therapy with methotrexate and topical glucocorticosteroids fails. Conclusion. Uveitis-associated JIA is one of the most disabling forms of JIA, since, despite timely and adequate management, very often it results in severe ocular complications: cataract, glaucoma and even blindness. Adalimumab, a human anti-TNFα monoclonal antibody, is available and it helps in achieving uveitis remission where methotrexate and topical glucocorticosteroids fail, as well as in delaying ocular complications. Keywords: juvenile idiopathic arthritis, uveitis, adalimumab, children.
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Chen, Judy L., Parinaz Abiri y Edmund Tsui. "Recent advances in the treatment of juvenile idiopathic arthritis–associated uveitis". Therapeutic Advances in Ophthalmology 13 (enero de 2021): 251584142098457. http://dx.doi.org/10.1177/2515841420984572.

Texto completo
Resumen
Juvenile idiopathic arthritis–associated uveitis has an estimated prevalence of 10–20% in patients with juvenile idiopathic arthritis, making it the most common cause of chronic anterior uveitis in children. Prompt treatment is important to prevent development of ocular complications and permanent vision loss. In this review, we will discuss the use of immunosuppression in treatment of juvenile idiopathic arthritis–associated uveitis. This will include the use of conventional immunosuppressants, such as methotrexate, biologic anti-tumor necrosis factor agents, such as adalimumab, as well as other anti-tumor necrosis factor agents, including infliximab and golimumab. In addition, we will discuss medications currently in clinical trials or under consideration for juvenile idiopathic arthritis–associated uveitis, including interleukin-6 inhibitors (tocilizumab) and Janus kinase inhibitors (tofacitinib, baricitinib).
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Thorne, Jennifer E. "Adalimumab in the Treatment of Uveitis in Juvenile Idiopathic Arthritis". New England Journal of Medicine 376, n.º 17 (27 de abril de 2017): 1682–83. http://dx.doi.org/10.1056/nejme1701811.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
Más fuentes

Tesis sobre el tema "Juvenile idiopathic arthritis, adalimumab, immunogenicity"

1

Marino, Achille. "Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations". Doctoral thesis, 2020. http://hdl.handle.net/2158/1190561.

Texto completo
Resumen
it is a prospective observational cohort study recruiting children with juvenile idiopathic arthritis (JIA) on adalimumab. The objective of the study is to assess the presence of anti-adalimumab antibodies and their clinical relevance in a cohort of JIA patients on adalimumab
Los estilos APA, Harvard, Vancouver, ISO, etc.

Actas de conferencias sobre el tema "Juvenile idiopathic arthritis, adalimumab, immunogenicity"

1

Kashchenko, E., E. Alexeeva, T. Bzarova, S. Valieva, R. Denisova, O. Lomakina, K. Isaeva, M. Soloshenko y A. Karaseva. "AB0951 Factors associated with response to adalimumab treatment in juvenile idiopathic arthritis". En Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.4011.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Caparello, Maria Costanza, Francesca Tirelli, Gabriele Simonini, Rolando Cimaz y Teresa Giani. "AB0948 PARADOXICAL TINEA AMIANTACEA IN A PATIENT WITH JUVENILE IDIOPATHIC ARTHRITIS RECEIVING ADALIMUMAB". En Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.4311.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Roshak, K., JM Sopczynski, RM Suehiro y L. Marshall. "THU0519 Etanercept, adalimumab and methotrexate utilization by juvenile idiopathic arthritis patients and the occurrence of uveitis". En Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.1857.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Ruperto, N., H. Brunner, K. Nanda, M. Toth, I. Foeldvari, J. Bohnsack, D. Milojevic et al. "THU0525 Safety of adalimumab ± methotrexate for the treatment of polyarticular juvenile idiopathic arthritis (PJIA): strive registry". En Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.2010.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Kordić, Nikolina Benco, Ana Kozmar y Alenka Gagro. "438 Relevance of adalimumab serum concentration and anti-adalimumab antibodies in secondary loss of response in patients with juvenile idiopathic arthritis". En 10th Europaediatrics Congress, Zagreb, Croatia, 7–9 October 2021. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2021. http://dx.doi.org/10.1136/archdischild-2021-europaediatrics.438.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Horneff, Gerd, Kisten Minden, Toni Hospach, Ivan Foeldvari, Peter Haas, Angelika Thon, Betina Rogalski et al. "SAT0502 EFFICACY AND SAFETY OF ADALIMUMAB IN JUVENILE IDIOPATHIC ARTHRITIS – 10 YEAR EXPERIENCE USING DATA OF THE BIKER REGISTRY". En Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.1457.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Klein, A., K. Minden, I. Foeldvari, G. Ganser, JP Haas, R. Trauzeddel, A. Hospach, F. Weller-Heinemann y G. Horneff. "THU0507 Long-term experience with adalimumab for the treatment of juvenile idiopathic arthritis. 5- year data from the german biker registry". En Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.3457.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Calvo, Inmaculada, Consuelo Modesto, Maria Montoro, Begoña Laiz, Estibaliz Iglesias, Estefanía Quesada-Masachs, B. Lopez-Montesinos et al. "FRI0555 INFLUENCE OF ANTI-TUMORNECROSIS FACTOR (TNF) DRUG IMMUNOGENICITY ON THE TREATMENT EFFECTIVENESS IN JUVENILE IDIOPATHIC ARTHRITIS (JIA) USING SERUM CALPROTECTIN AS A DISEASE ACTIVITY MARKER. MULTICENTER STUDY. ITACA STUDY". En Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7963.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.

Informes sobre el tema "Juvenile idiopathic arthritis, adalimumab, immunogenicity"

1

Li, Biao, Haoran Li, Li Zhang y Yanlin Zheng. Efficacy and safety of adalimumab in the treatment of Juvenile Idiopathic Arthritis-Associated Uveitis: a meta-analysis and systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, noviembre de 2020. http://dx.doi.org/10.37766/inplasy2020.11.0002.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
También puede estar interesado en las bibliografías ampliadas sobre el tema "Juvenile idiopathic arthritis, adalimumab, immunogenicity" para tipos de fuentes particulares:
Artículos de revistas
Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!

Pasar a la bibliografía